Comprehensive online regulatory training aligned with Health Canada, FDA, EMA, and ICH standards — trusted by Canadian regulatory professionals, sponsors, and CROs. Self-paced. 21 CFR Part 11 compliant certificates. Inspection-ready training records.
Canada has a robust regulatory framework for pharmaceuticals, biologics, and medical devices, governed by Health Canada under the Food and Drugs Act and its regulations. Canadian regulatory professionals must navigate requirements for clinical trials (Part C, Division 5), pharmaceutical submissions (e.g., New Drug Submissions - NDS), and biologics licensing, all while aligning with ICH guidelines. Furthermore, the close integration with the U.S. market means that a strong understanding of FDA regulations is essential for many Canadian professionals working on global submissions.
| Market | Framework | Application |
|---|---|---|
| Health Canada | Food and Drugs Act & Regulations | Overall legislative authority for drugs and devices |
| Health Canada | Guidance for Industry: Product Monograph | Core document for prescription drug submissions |
| Health Canada | ICH E6(R3) GCP (adopted April 1, 2026) | Ethical and scientific quality standards for clinical trials |
| US FDA | 21 CFR Parts 50, 56, 312, 314, 600, 601 | Essential for submissions to the U.S. market |
| ICH | ICH Guidelines (E, M, Q, S series) | International harmonisation for global drug development |
All courses are self-paced, available online, and include 21 CFR Part 11 compliant certificates with verifiable IDs — accepted as documented training records during regulatory inspections.
Comprehensive certification covering the global pharmaceutical regulatory landscape. This program provides end-to-end knowledge of the drug development lifecycle with specific focus on the FDA, EMA, and Health Canada requirements, as well as harmonization initiatives under ICH. It covers all major application types including IND, NDA, ANDA, and BLA, making it the ideal foundational program for Canadian professionals working on both domestic and international submissions.
A comprehensive, end-to-end understanding of the IND framework as regulated by the U.S. FDA. While US-centric, this knowledge is critical for Canadian sponsors and CROs conducting clinical trials in the US or submitting Clinical Trial Applications (CTAs) to Health Canada that reference US data. The course covers 21 CFR Part 312, safety reporting, and sponsor responsibilities.
Enroll in Regulatory AffairsThis program covers the entire drug development and approval process, focusing on the preparation of a complete New Drug Application (NDA) organized into the five CTD modules. This training is essential for Canadian professionals involved in submitting NDSs to Health Canada, as the CTD format is the international standard used by both agencies.
Enroll in Mastering the NDAProvides comprehensive knowledge of the planning, preparation, and submission of BLAs to the FDA. This is crucial for Canadian biotech companies and professionals seeking to enter the U.S. market with biological products. The course covers CMC, nonclinical and clinical data requirements, and FDA review processes.
Enroll in Biologics License ApplicationCovers the entire orphan drug development and approval process, from rare disease discovery through NDA submission and maintenance of seven-year exclusivity. This is highly relevant for Canadian companies developing therapies for rare diseases and seeking designation from both the FDA and Health Canada.
Enroll in Mastering the Orphan Drug NDAProvides an in-depth understanding of the regulatory requirements for preparing and submitting Abbreviated New Drug Applications (ANDAs) to the U.S. FDA. This is vital for Canadian generic pharmaceutical companies looking to export to the U.S. market.
Enroll in ANDA Compliance TrainingRegulatory training is a critical requirement for all personnel involved in the research, development, and submission of pharmaceutical, biologic, and medical device products in Canada. Staying current with evolving Health Canada, FDA, and ICH standards is essential for ensuring compliance and successful market access.
Health Canada conducts inspections of pharmaceutical manufacturers, clinical trial sites, and distributors to verify compliance with the Food and Drugs Act and its regulations. Inadequate regulatory training can lead to serious findings that impact your organization's ability to operate and market products in Canada.
Common Health Canada inspection observations related to regulatory and quality training include:
Our 21 CFR Part 11 compliant certificates provide auditable, documented training records that FDA investigators accept during inspections.
Canada's membership in the Pharmaceutical Inspection Co-operation Scheme (PIC/S) has significant implications for regulatory affairs professionals, extending beyond just manufacturing and distribution. The international harmonization of standards directly impacts how global drug submissions are prepared and reviewed.
PIC/S alignment means that the technical and quality standards (like ICH guidelines) are interpreted consistently across 55+ member countries. For a Canadian regulatory professional, training that covers PIC/S-aligned principles provides a crucial framework for preparing submissions (like NDS, NDA, or BLA) that are more readily accepted by multiple international regulators, including the FDA and EMA.
A deep understanding of PIC/S-aligned GMP and quality principles is essential for RA professionals who author CMC (Chemistry, Manufacturing, and Controls) sections of regulatory dossiers. This expertise is recognized by international partners and is critical for successful global product registration.
Canadian companies often pursue a global launch strategy. RA professionals must be adept at navigating the nuances between Health Canada, FDA, and EMA requirements. Our courses cover the core regulatory principles recognized by all PIC/S member authorities, equipping you to build effective, multi-market regulatory strategies.
Training your entire QA, warehouse, or transport team? We offer group enrollment for Canadian pharmaceutical logistics companies of all sizes. Group quotes provided within 24 hours.
| Feature | GxP Trainings |
|---|---|
| Health Canada & FDA Submissions | |
| ICH Guidelines (Q, S, E Series) | |
| CTD/eCTD Format | |
| ICH Q9 (Quality Risk Management) | |
| Health Canada Inspections | |
| 21 CFR Part 11 Compliant Certificate | |
| Self-Paced & Online | |
| Instant certificate download | |
| Verifiable certificate ID | |
| Group / corporate enrollment |
Yes. Health Canada does not mandate a specific training delivery format. The key is that the training is documented, role-appropriate, and effective. Our 21 CFR Part 11 compliant certificates provide verifiable proof of training that is recognized during inspections.
Yes. We offer corporate and group enrollment options for teams of all sizes. Contact us for a custom quote.
All courses include lifetime access — study at your own pace, on your own schedule.
Yes. Each certificate includes a unique verifiable ID that can be checked at gxptrainings.com/verify-certificate/
Equip yourself and your team with the Regulatory Affairs knowledge and documented training records required for Health Canada, FDA, and WHO inspection readiness.